Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Gynecol Endocrinol
; 30(8): 587-92, 2014 Aug.
Article
en En
| MEDLINE
| ID: mdl-24819316
ABSTRACT
OBJECTIVE:
The efficacy of vascular endothelial growth factor (VEGF), COX-2, calcium and aromatase inhibitors in an ovarian hyperstimulation syndrome (OHSS) rat model was tested.METHODS:
One hundred and eight female Wistar rats were randomly divided in nine groups. The control group received saline, while the OHSS group received rec-FSH for 4 consecutive days. The other seven groups received rec-FSH (4d) and Bevacizumab twice, Parecoxib daily, Verapamil daily, Parecoxib daily and Bevacizumab twice, Verapamil daily and Bevacizumab twice, Parecoxib and Verapamil daily, Letrozole and Meloxicam daily, respectively. All groups received also hCG at the 5th day.RESULTS:
All intervention groups were characterized by reduced vascular permeability compared to the OHSS group, which in the groups of Verapamil (Calcium inhibition) and Parecoxib + Verapamil (COX-2 + Calcium inhibition) presented significant statistical difference. The Verapamil group showed the lowest corpus luteum formation, while the Parecoxib (COX-2 inhibition), the Parecoxib + Verapamil (COX-2 + Calcium inhibition), the Bevacizumab + Parecoxib (VEGF + COX-2 inhibition) and the Bevacizumab + Verapamil (VEGF + Calcium inhibition) groups were also characterized by lower corpus luteum numbers compared to the OHSS group. Furthermore, lower graafian follicle formation was observed in the above groups, while the ovarian weight and the hormonal profile were not significantly affected.CONCLUSIONS:
Studying the different check points of the VEGF pathway, we conclude that targeting calcium pathways could be beneficial for the vascular permeability control in an OHSS animal model.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Verapamilo
/
Síndrome de Hiperestimulación Ovárica
/
Señalización del Calcio
/
Factor A de Crecimiento Endotelial Vascular
/
Inhibidores de la Ciclooxigenasa 2
/
Anticuerpos Monoclonales Humanizados
/
Isoxazoles
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Gynecol Endocrinol
Año:
2014
Tipo del documento:
Article
País de afiliación:
Grecia